

July 16, 2024

To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.,
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001

To,
The Manager - Listing,
National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Ref: Scrip Code: 543322

Ref: Scrip Name: GLS

Dear Sir/Madam,

Sub: Intimation pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) - Minimum Public Shareholding (MPS).

With reference to our intimation dated July 10, 2024, we wish to inform you that Glenmark Pharmaceuticals Limited and Mr. Glenn Mario Saldanha, One of the promoter and promoter Group of Glenmark Life Sciences Limited (the “Company”), have informed the Company that they have sold 96,09,571 and 7,800 Equity Shares, respectively, aggregating to 9,617,371 Equity Shares representing 7.85% of the total issued and paid-up equity share capital of the Company as on date, in accordance with SEBI circular no. SEBI/HO/MRD/MRD-PoD3/P/CIR/2023/10 dated January 10, 2023 to achieve the minimum public shareholding requirements.

With the aforementioned sale of shares, the shareholding of the Promoter and Promoter Group in the Company has reduced from 82.85% of the paid-up equity share capital of the Company to 75.00073% of the paid-up equity share capital of the Company.

The remaining 0.00073% is on account of the Open Offer which was concluded on March 5, 2024. It is submitted that otherwise MPS obligation is achieved for the IPO.

As regards achieving MPS of 0.00073%, the Company has time period of one year from March 5, 2024 and the same would be achieved within the stipulated time frame and in the manner specified by SEBI from time to time.

This is for your kind information and records.

Yours faithfully,
For Glenmark Life Sciences Limited

Rudalf Corriea
Company Secretary & Compliance Officer